Q: Your last direct response on FLGT was Nov, 2021. Could you update your opinion on a value/growth basis, with a focus on "core genetic" testing elements rather than Covid testing. It seems to be growing nicely in core businesses, e.g., cancer NGS, has a very strong cash horde (from covid work) and, to me, ticks both value and growth boxes.
Thx, John
Thx, John